

John D Phillips

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7931376/publications.pdf>

Version: 2024-02-01

109
papers

5,033
citations

117625

34
h-index

95266

68
g-index

115
all docs

115
docs citations

115
times ranked

5309
citing authors

#	ARTICLE	IF	CITATIONS
1	Acellular human amniotic fluid protects the ischemic/reperfused rat myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, , .	3.2	3
2	MRP5 and MRP9 play a concerted role in male reproduction and mitochondrial function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	9
3	Metal content and kinetic properties of yeast RNA lariat debranching enzyme Dbr1. <i>Rna</i> , 2022, 28, 927-936.	3.5	3
4	Hepatocellular Carcinoma in Acute Hepatic Porphyrrias: Results from the Longitudinal Study of the U.S. Porphyrrias Consortium. <i>Hepatology</i> , 2021, 73, 1736-1746.	7.3	32
5	A pilot trial of human amniotic fluid for the treatment of COVID-19. <i>BMC Research Notes</i> , 2021, 14, 32.	1.4	6
6	Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , 2021, 11, e045162.	1.9	3
7	Measurement of Immature Reticulocytes in Dried Blood Spots by Mass Spectrometry. <i>Clinical Chemistry</i> , 2021, 67, 1071-1079.	3.2	9
8	The ubiquitous mitochondrial protein unfoldase CLPX regulates erythroid heme synthesis by control of iron utilization and heme synthesis enzyme activation and turnover. <i>Journal of Biological Chemistry</i> , 2021, 297, 100972.	3.4	20
9	The immunometabolite itaconate inhibits heme synthesis and remodels cellular metabolism in erythroid precursors. <i>Blood Advances</i> , 2021, 5, 4831-4841.	5.2	8
10	ABCB6 Polymorphisms are not Overly Represented in Patients with Porphyria. <i>Blood Advances</i> , 2021, , .	5.2	2
11	Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute intermittent porphyria. <i>Genetics in Medicine</i> , 2020, 22, 590-597.	2.4	8
12	The mitochondrial metal transporters mitoferrin1 and mitoferrin2 are required for liver regeneration and cell proliferation in mice. <i>Journal of Biological Chemistry</i> , 2020, 295, 11002-11020.	3.4	25
13	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. <i>New England Journal of Medicine</i> , 2020, 382, 2289-2301.	27.0	350
14	Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. <i>Nature Immunology</i> , 2020, 21, 178-185.	14.5	186
15	Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 309-313.	1.1	9
16	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. <i>Genetics in Medicine</i> , 2019, 21, 2605-2613.	2.4	16
17	Heme biosynthesis and the porphyrias. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 164-177.	1.1	116
18	Harderoporphyria: Case of lifelong photosensitivity associated with compound heterozygous coproporphyrinogen oxidase (CPOX) mutations. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 19, 100457.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyrin. <i>New England Journal of Medicine</i> , 2019, 380, 549-558.	27.0	194
20	Feasibility of cellular bioenergetics as a biomarker in porphyria patients. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 19, 100451.	1.1	17
21	Identification and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute intermittent porphyria. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 186-194.	3.6	17
22	Overexpression of the peroxin Pex34p suppresses impaired acetate utilization in yeast lacking the mitochondrial aspartate/glutamate carrier Agc1p. <i>FEMS Yeast Research</i> , 2019, 19, .	2.3	4
23	Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 391-395.	1.1	7
24	Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria. <i>Human Molecular Genetics</i> , 2019, 28, 1755-1767.	2.9	17
25	Hemozoin produced by mammals confers heme tolerance. <i>ELife</i> , 2019, 8, .	6.0	38
26	Regulation of Erythroid Heme Synthesis By the Mitochondrial Clpx Unfoldase. <i>Blood</i> , 2019, 134, 427-427.	1.4	0
27	Identification and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute intermittent porphyria. <i>Journal of Inherited Metabolic Disease</i> , 2018, 42, 186.	3.6	9
28	Reply. <i>Hepatology</i> , 2018, 67, 803-804.	7.3	0
29	Longitudinal Analysis of Erythrocyte and Plasma Protoporphyrin Levels in Patients with Protoporphyria. <i>Journal of applied laboratory medicine</i> , The, 2018, 3, 213-221.	1.3	3
30	Cirrhosis in Hemochromatosis: Independent Risk Factors in 368 HFE p.C282Y Homozygotes. <i>Annals of Hepatology</i> , 2018, 17, 871-879.	1.5	25
31	Hrg1 promotes heme-iron recycling during hemolysis in the zebrafish kidney. <i>PLoS Genetics</i> , 2018, 14, e1007665.	3.5	21
32	FAM210B is an erythropoietin target and regulates erythroid heme synthesis by controlling mitochondrial iron import and ferrochelatase activity. <i>Journal of Biological Chemistry</i> , 2018, 293, 19797-19811.	3.4	30
33	Glutamine via α -ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis. <i>Blood</i> , 2018, 132, 987-998.	1.4	53
34	Synthesis of comb-shaped DNA using a non-nucleosidic branching phosphoramidite. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 4659-4664.	2.8	2
35	Target of Erythropoietin, Fam210b, Regulates Erythroid Heme Synthesis By Control of Mitochondrial Iron Import and Regulation of Fech Activity. <i>Blood</i> , 2018, 132, 849-849.	1.4	1
36	Two novel mutations in TMPRSS6 associated with iron-refractory iron deficiency anemia in a mother and child. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 38-40.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Acute hepatic porphyrias: Recommendations for evaluation and long-term management. <i>Hepatology</i> , 2017, 66, 1314-1322.	7.3	122
38	Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyrinuria and X-linked Protoporphyrinuria. <i>JAMA Dermatology</i> , 2017, 153, 789.	4.1	70
39	GNPAT p.D519G is independently associated with markedly increased iron stores in HFE p.C282Y homozygotes. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 63, 15-20.	1.4	13
40	Mutation in human <i>CLPX</i> elevates levels of δ -aminolevulinic acid synthase and protoporphyrin IX to promote erythropoietic protoporphyria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8045-E8052.	7.1	69
41	Reductions in the mitochondrial ABC transporter <i>Abcb10</i> affect the transcriptional profile of heme biosynthesis genes. <i>Journal of Biological Chemistry</i> , 2017, 292, 16284-16299.	3.4	28
42	Erythropoietin signaling regulates heme biosynthesis. <i>ELife</i> , 2017, 6, .	6.0	36
43	A Novel Role for Progesterone Receptor Membrane Component 1 (PGRMC1): A Partner and Regulator of Ferrochelatase. <i>Biochemistry</i> , 2016, 55, 5204-5217.	2.5	89
44	Regulation of intracellular heme trafficking revealed by subcellular reporters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5144-52.	7.1	98
45	Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria. <i>Blood</i> , 2016, 128, 2318-2318.	1.4	3
46	The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda. <i>PLoS ONE</i> , 2016, 11, e0163322.	2.5	7
47	GNPAT p.D519G is Independently Associated with Markedly Increased Iron Stores in HFE p.C282Y Homozygotes. <i>Blood</i> , 2016, 128, 3617-3617.	1.4	0
48	A Dominant Mutation in Mitochondrial Unfoldase CLPX Results in Erythropoietic Protoporphyrinuria. <i>Blood</i> , 2016, 128, 77-77.	1.4	0
49	Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria. <i>Blood</i> , 2015, 126, 257-261.	1.4	31
50	Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver. <i>Molecular Medicine</i> , 2015, 21, 487-495.	4.4	51
51	Noncanonical coproporphyrin-dependent bacterial heme biosynthesis pathway that does not use protoporphyrin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2210-2215.	7.1	143
52	Exome sequencing for molecular characterization of non-HFE hereditary hemochromatosis. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 101-103.	1.4	4
53	Afamelanotide for Erythropoietic Protoporphyrinuria. <i>New England Journal of Medicine</i> , 2015, 373, 48-59.	27.0	206
54	A method for determining δ -aminolevulinic acid synthase activity in homogenized cells and tissues. <i>Clinical Biochemistry</i> , 2015, 48, 788-795.	1.9	11

#	ARTICLE	IF	CITATIONS
55	Identification of the Mitochondrial Heme Metabolism Complex. PLoS ONE, 2015, 10, e0135896.	2.5	88
56	Identification of Polymorphic Gnpat As a Risk Factor for Porphyria Cutanea Tarda. Blood, 2015, 126, 3353-3353.	1.4	0
57	Fam210b Is Required for Optimal Cellular and Mitochondrial Iron Uptake during Erythroid Differentiation. Blood, 2015, 126, 405-405.	1.4	2
58	RNAi-mediated silencing of hepatic <i>Alas1</i> effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7777-7782.	7.1	99
59	Acute Porphyrias in the USA: Features of 108 Subjects from Porphyrias Consortium. American Journal of Medicine, 2014, 127, 1233-1241.	1.5	185
60	TMEM14C is required for erythroid mitochondrial heme metabolism. Journal of Clinical Investigation, 2014, 124, 4294-4304.	8.2	62
61	Porphyria Cutanea Tarda. Handbook of Porphyrin Science, 2013, , 219-261.	0.8	2
62	Loss-of-Function Ferrochelatase and Gain-of-Function Erythroid-Specific 5-Aminolevulinatase Mutations Causing Erythropoietic Protoporphyrinemia and X-Linked Protoporphyrinemia in North American Patients Reveal Novel Mutations and a High Prevalence of X-Linked Protoporphyrinemia. Molecular Medicine, 2013, 19, 26-29.	4.4	74
63	Inducing Iron Deficiency Dramatically Improves Erythropoiesis and Photosensitivity In Congenital Erythropoietic Porphyria (CEP). Blood, 2013, 122, 3442-3442.	1.4	0
64	ABCB6 Mutations Cause Ocular Coloboma. American Journal of Human Genetics, 2012, 90, 40-48.	6.2	75
65	Uroporphyrin in the <i>Cyp1a2</i> mouse. Blood Cells, Molecules, and Diseases, 2011, 47, 249-254.	1.4	10
66	Cellular Distribution of Porphyrins In Porphyria Cutanea Tarda. Blood, 2010, 116, 165-165.	1.4	3
67	Reduction of porphyrins to porphyrinogens with palladium on carbon. Analytical Biochemistry, 2009, 384, 74-78.	2.4	11
68	Substrate Shuttling between Active Sites of Uroporphyrinogen Decarboxylase Is Not Required to Generate Coproporphyrinogen. Journal of Molecular Biology, 2009, 389, 306-314.	4.2	19
69	Structure and Mechanistic Implications of a Uroporphyrinogen III Synthase Product Complex. Biochemistry, 2008, 47, 8648-8655.	2.5	32
70	Down-regulation of hepcidin in porphyria cutanea tarda. Blood, 2008, 112, 4723-4728.	1.4	38
71	The Uroporphomethene Inhibitor Causative for Porphyria Cutanea Tarda (PCT) Is Generated by Oxidation of Hydroxymethylbilane (HMB). Blood, 2008, 112, 3454-3454.	1.4	1
72	Hepatic ABC Transporter Expression in A Hemochromatosis-Linked Murine Model of Porphyria Cutanea Tarda. FASEB Journal, 2008, 22, 921.21.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Identification of Two Novel Mutations in the CYB5R3 Gene in Five Cases of Type I Methemoglobinemia. <i>Blood</i> , 2008, 112, 3854-3854.	1.4	0
74	A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5079-5084.	7.1	124
75	Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. <i>Blood</i> , 2007, 109, 2618-2621.	1.4	155
76	Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria (HEP). <i>Translational Research</i> , 2007, 149, 85-91.	5.0	15
77	Up-Regulation of miR-195 Expression Leads to Decreased Expression of Basic Fibroblast Growth Factor in CLL Patients Treated with DNA Methylation Inhibitors.. <i>Blood</i> , 2007, 110, 3183-3183.	1.4	11
78	Dual gene defects involving delta-aminolaevulinatase and coproporphyrinogen oxidase in a porphyria patient. <i>British Journal of Haematology</i> , 2006, 132, 237-243.	2.5	24
79	Biosynthesis of heme in mammals. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006, 1763, 723-736.	4.1	389
80	DNA Methylation Inhibitors Upregulate MiRNA Expression in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006, 108, 2257-2257.	1.4	4
81	Upregulation of SOCS-1 and Downregulation of miR-214 Correlate with Disease Course in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006, 108, 4313-4313.	1.4	0
82	HAMP and HVJ as Candidate Modifier Genes in Type1 Hereditary Hemochromatosis with High Iron Burden and in Porphyria Cutanea Tarda (PCT).. <i>Blood</i> , 2006, 108, 1544-1544.	1.4	0
83	An Inhibitor of Uroporphyrinogen Decarboxylase (URO-D) Causes Porphyria Cutanea Tarda (PCT).. <i>Blood</i> , 2006, 108, 270-270.	1.4	6
84	Fast track to the porphyrias. <i>Nature Medicine</i> , 2005, 11, 1049-1050.	30.7	17
85	Identification of a novel mutation in the L-ferritin IRE leading to hereditary hyperferritinemia-cataract syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2005, 134A, 77-79.	1.2	14
86	Attenuation of polychlorinated biphenyl induced uroporphyrinogen decarboxylase activity by iron deprivation. <i>Environmental Toxicology and Pharmacology</i> , 2005, 20, 417-423.	4.0	7
87	Congenital Erythropoietic Porphyria, β -Thalassemia Intermedia and Thrombocytopenia Due to a GATA1 Mutation.. <i>Blood</i> , 2005, 106, 515-515.	1.4	5
88	Global DNA Hypermethylation in Chronic Lymphocytic Leukemia Correlates with Progressive Disease.. <i>Blood</i> , 2005, 106, 5006-5006.	1.4	1
89	Clonal Marking of Mouse Hematopoietic Stem and Lymphoid Progenitor Cell Populations.. <i>Blood</i> , 2005, 106, 5544-5544.	1.4	0
90	Crystal Structure of the Oxygen-dependant Coproporphyrinogen Oxidase (Hem13p) of <i>Saccharomyces cerevisiae</i> . <i>Journal of Biological Chemistry</i> , 2004, 279, 38960-38968.	3.4	71

#	ARTICLE	IF	CITATIONS
91	Identification of a Human Heme Exporter that Is Essential for Erythropoiesis. <i>Cell</i> , 2004, 118, 757-766.	28.9	375
92	Crystal Structure of Coproporphyrinogen Oxidase (CPO).. <i>Blood</i> , 2004, 104, 52-52.	1.4	0
93	Structural basis for tetrapyrrole coordination by uroporphyrinogen decarboxylase. <i>EMBO Journal</i> , 2003, 22, 6225-6233.	7.8	72
94	Crystal Structure of a Biliverdin IX β Reductase Enzymeâ€“Cofactor Complex. <i>Journal of Molecular Biology</i> , 2002, 319, 1199-1210.	4.2	56
95	Uroporphyrin in the uroporphyrinogen decarboxylase-deficient mouse: Interplay with siderosis and polychlorinated biphenyl exposure. <i>Hepatology</i> , 2002, 36, 805-811.	7.3	11
96	Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase. <i>Blood</i> , 2001, 98, 3179-3185.	1.4	35
97	Accelerated development of uroporphyrin in mice heterozygous for a deletion at the uroporphyrinogen decarboxylase locus. <i>Journal of Biochemical and Molecular Toxicology</i> , 2001, 15, 287-293.	3.0	9
98	Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. <i>Translational Research</i> , 2000, 136, 482-488.	2.3	40
99	CYP3A-inducing agents and the attenuation of uroporphyrin accumulation and excretion in a rat model of porphyria cutanea tarda. <i>Biochemical Pharmacology</i> , 2000, 60, 1325-1331.	4.4	13
100	Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. <i>Blood</i> , 2000, 95, 1565-1571.	1.4	181
101	The Heme Biosynthesis Pathway and Clinical Manifestations of Abnormal Function. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]</i> , 1999, 00, Unit 8.1.	1.1	0
102	Measurement of Uroporphyrinogen Decarboxylase Activity. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]</i> , 1999, 00, Unit 8.4.	1.1	6
103	Crystal Structure of <i>Trichomonas foetus</i> Inosine-5â€“monophosphate Dehydrogenase and the Enzymeâ€“Product Complexâ€. <i>Biochemistry</i> , 1997, 36, 10666-10674.	2.5	57
104	Cytochrome P450 Induction, Uroporphyrinogen Decarboxylase Depression, Porphyrin Accumulation and Excretion, and Gender Influence in a 3-Week Rat Model of Porphyria Cutanea Tarda. <i>Toxicology and Applied Pharmacology</i> , 1997, 147, 289-299.	2.8	34
105	Characterization and crystallization of human uroporphyrinogen decarboxylase. <i>Protein Science</i> , 1997, 6, 1343-1346.	7.6	37
106	Mutational analysis of human uroporphyrinogen decarboxylase. <i>BBA - Proteins and Proteomics</i> , 1996, 1298, 294-304.	2.1	18
107	Iron Regulates the Intracellular Degradation of Iron Regulatory Protein 2 by the Proteasome. <i>Journal of Biological Chemistry</i> , 1995, 270, 21645-21651.	3.4	264
108	Energy metabolism in free-living, â€“large-eatingâ€“ and â€“small-eatingâ€“ women: studies using 2H218O. <i>British Journal of Nutrition</i> , 1994, 72, 21-31.	2.3	23

#	ARTICLE	IF	CITATIONS
109	Differences in energy metabolism between normal weight "large-eating"™ and "small-eating"™ women. British Journal of Nutrition, 1992, 68, 31-44.	2.3	15